Following the official launch last month, the Epilepsy Research Institute has announced the appointment of their next Chief Executive, Rosemarie Pardington. Rosemarie has been closely involved in the plans to set up the new Institute as Deputy CEO at Young Epilepsy and will take up the role at the end of January 2024.
The Institute is the world’s first national research institute dedicated to epilepsy and will serve as the central hub for the epilepsy research community. Its mission is to radically advance research into the causes, prevention and treatment of epilepsy and its associated conditions. The comprehensive research strategy developed by the national research collaborative #Every1EndingEpilepsy will provide the foundation for this.
Working at Young Epilepsy for the last 7 years, I truly appreciate the positive impact epilepsy research makes to the lives of those with epilepsy and I feel extremely honoured to have been offered this position to enable me to continue to advance this important work.Rosemarie Pardington
The Epilepsy Research Institute’s Founding Partners include Young Epilepsy, Epilepsy Action, Epilepsy Scotland, and the International League Against Epilepsy British Branch. By working together, the Institute will operationalise the Top Ten priorities of the UK Epilepsy Priority Setting Partnership.
As one of the founding partners of the Institute, Young Epilepsy is delighted that our colleague, Rosemarie Pardington, is to become the new CEO. This will further strengthen our joint working as part of this ground-breaking strategic collaboration across the epilepsy research community. We wish Rosemarie and the Institute team all the very best for the future.Mark Devlin, Young Epilepsy CEO
The Institute aims to strengthen the epilepsy research ecosystem by driving strategic investment and developing partnerships and collaborations between academia, the NHS, industry, funders, and patient groups. Central to this will be a culture of advocating and actioning the research priorities of people affected by epilepsy.
Rosemarie and I have worked closely for five years, and I could not be more delighted that she will be our next CEO. Rosemarie’s understanding of the needs of people affected by epilepsy, her experience, expertise, and strategic leadership will guide us towards realising a transformational future for epilepsy research.Maxine Smeaton, ERIUK Chief Executive
